Review
Version 1
Preserved in Portico This version is not peer-reviewed
Regulation of Ferroptosis in Lung Adenocarcinoma
Version 1
: Received: 10 September 2023 / Approved: 12 September 2023 / Online: 12 September 2023 (10:36:16 CEST)
A peer-reviewed article of this Preprint also exists.
Wei, X.; Li, X.; Hu, S.; Cheng, J.; Cai, R. Regulation of Ferroptosis in Lung Adenocarcinoma. Int. J. Mol. Sci. 2023, 24, 14614. Wei, X.; Li, X.; Hu, S.; Cheng, J.; Cai, R. Regulation of Ferroptosis in Lung Adenocarcinoma. Int. J. Mol. Sci. 2023, 24, 14614.
Abstract
Lung adenocarcinoma (LUAD) is the most common lung cancers, which accounts for about 35%-40% of all lung cancer patients. Despite therapeutic advancements in recent years, the overall survival time of the LUAD patients still remain poor, especially KRAS mutant LUAD. Therefore, it is necessary to further explore novel targets and drugs to improve the prognosis of LUAD. Ferroptosis, an iron-dependent regulated cell death (RCD）caused by lipid peroxidation, has attracted much attention recently as an alternative target for apoptosis in LUAD therapy. Ferroptosis has been found closely related with LUAD, at its every stage, including initiation, proliferation and progression. In this review, we will provide a comprehensive overview on ferroptosis mechanisms, it’s regulation in LUAD, and application of targeting ferroptosis for LUAD therapy.
Keywords
ferroptosis; regulation; lung adenocarcinoma; therapy
Subject
Biology and Life Sciences, Cell and Developmental Biology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
